<DOC>
	<DOC>NCT02719639</DOC>
	<brief_summary>Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need treatment with two long-acting bronchodilators, is not available. This is a self-controlled study design enrolling consented COPD patients who will be treated with Spiolto Respimat according to the approved Summary of Product Characteristics (SmPC).</brief_summary>
	<brief_title>OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)</brief_title>
	<detailed_description>Purpose: Study Design:</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criteria: 1. Written informed consent prior to participation 2. Female and male patients with more or equal to 40 years of age 3. Patients diagnosed with COPD and requiring longacting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto Respimat Summary of Product Characteristics (SmPC) and chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline recommendation Exclusion criteria: 1. Patients with contraindications according to Spiolto Respimat SmPC 2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months 3. Patients continuing LABAICS (inhaled corticosteroid) treatment should not be additionally treated with Spiolto Respimat in order to avoid a double dosing of longacting betaagonists 4. Patients for whom further followup is not possible at the enrolling site during the planned study period of approx. 6 weeks 5. Pregnancy and lactation 6. Patients currently listed for lung transplantation 7. Current participation in any clinical trial or any other noninterventional study of a drug or device</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>